Status
Conditions
About
This study intends to prospectively enroll high-risk pregnant women to establish a multicenter cohort. By combining maternal basic characteristics, medical history, early pregnancy ultrasound, and biological markers, we aim to construct a joint predictive model for MVM-FGR.
Full description
Clinical guidelines do not recommend clinical screening for MVM-FGR in low-risk populations. Predictive models for FGR are often based on preeclampsia prediction models or Down syndrome serum screening models, which have limited utility. This study aims to establish a multi-center prospective cohort of pregnant women at high risk for FGR. We will collect baseline characteristics of pregnant women, ultrasound measurements of fetal growth, structural scans, maternal-fetal Doppler blood flow, as well as maternal serum and plasma in first and mid-trimester. Serum and plasma biomarker testing will be conducted. We will regularly observe fetal growth data, maternal-fetal complications during pregnancy, and collect delivery information, conditions of the newborn and placental pathology results after birth. By integrating maternal medical history, serum and plasma biomarkers, Doppler ultrasound, and other factors, we will establish a combined predictive model for early and mid-term MVM-FGR.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
Pregnant women with gestational age of <14 weeks
Maternal age between 18 and 45 years old
With at least one of FGR high risk factors:
Or with at least two of the following FGR high risk factors:
Maternal age 35~40 years
BMI ≥ 28 kg/m2 or BMI < 18.5 kg/m2
Conception with assisted reproductive technology
Interval from previous delivery: > 5 years or < 6 months
Exclusion Criteria:
Presence of fetal genetic abnormalities or severe structural abnormalities in prenatal ultrasound or genetic testing.
Loading...
Central trial contact
Jianping Chen, Master
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal